Most importantly, DAC and IL-33 synergistically enhanced the expression of PD-1 within the TME and the percentages of PD-1 expressing tumor-infiltrating CD8 and CD4 T cells, resulting in improved in vivo response to PD-1 blockade. The gene discussed is CD8A; the disease is neoplasm.